All St. Jude Children’s Research Hospital articles
-
NewsInactive H5N1 influenza virus in pasteurized milk poses minimal health risks
Proteins and genetic material from H5N1 influenza viruses have been found in pasteurized milk in the United States, but a study shows those inactive viral pieces represent little to no health risk. H5N1-contaminated milk that was pasteurized did not significantly affect the immune system.
-
NewsH5N1 found in dairy cattle retains preference for infecting birds, representing low risk to humans
Avian influenza virus from the ongoing outbreak in dairy cattle appears to be keeping its bird-infecting features rather than adapting to better infect other mammals, according to a new study.
-
NewsNovel breath test shows promise for diagnosing and monitoring bacterial infections
A new, non-invasive breath test has emerged as a potential breakthrough for rapidly diagnosing bacterial infections and tracking treatment effectiveness.
-
NewsCurrent antivirals likely less effective against severe infection caused by bird flu virus in cows’ milk
Scientists found that in a preclinical model, two FDA–approved flu antivirals generally did not successfully treat severe H5N1 infections. Meanwhile, the route of infection, whether through the eye, the nose or the mouth, significantly impacts effectiveness.
-
NewsStudy reveals oleoyl-ACP-hydrolase underpins lethal respiratory viral disease
Respiratory infections can be severe, even deadly, in some individuals, but not in others. Scientists have gained new understanding of why this is the case by uncovering an early molecular driver that underpins fatal disease.
-
NewsScientists get to the bottom of COVID’s worst pediatric complication
Scientists investigating multisystem inflammatory syndrome in children (MIS-C) found their immune systems had latched onto a part of the coronavirus that closely resembles a protein found in their bodies, launching an attack on their own tissues.
-
NewsNew approach could address antibiotic resistance to Mycobacterium abscessus
Scientists have designed new versions of the drug spectinomycin that overcome efflux, the main mechanism driving resistance.